ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "skin"

  • Abstract Number: 1759 • ACR Convergence 2021

    An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients

    Emily Keyes1, Anisha Jobanputra2, Madison Grinnell3, Rui Feng4, Thomas Vazquez5, DeAnna Diaz6 and Victoria Werth7, 1Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 2Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, 4University of Pennsylvania Department of Biostatistics, Philadelphia, PA, 5FIU Wertheim College of Medicine, Virginia Beach, VA, 6Philadelphia College of Medicine, Philadelphia, PA, 7Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…
  • Abstract Number: 1784 • ACR Convergence 2021

    Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry

    Alexis Ogdie-Beatty1, Bruce Strober2, Mark Lebwohl3, Angel Cronin4, Tin-chi Lin4, Hyung-Joo Kang4, Nicole Middaugh4, Jacqueline O’Brien4, Shauna Jardon5, Sven Richter6, Yuri Klyachkin7 and Philip Mease8, 1University of Pennsylvania, Philadelphia, PA, 2Yale University, New Haven, CT, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4CorEvitas, LLC, Waltham, MA, 5Amgen Inc., Gilbert, AZ, 6Amgen Inc., Thousand Oaks, CA, 7Amgen Inc., Lexington, KY, 8Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

    Background/Purpose: Patients (pts) with mild to moderate psoriasis (PsO) and musculoskeletal disease burden may be diagnosed with PsA upon referral to a rheumatologist. Early intervention…
  • Abstract Number: 1857 • ACR Convergence 2021

    Ultra-High Frequency Ultrasound Compared to Durometry and Skin Score for Cutaneous Assessment in Systemic Sclerosis

    Marco Di Battista1, Saverio Vitali2, Simone Barsotti3, Alessandra Della Rossa4, Valentina Dini5, Marco Romanelli5 and Marta Mosca3, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Radiology Unit - University of Pisa, Pisa, Italy, 3Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 4Rheumatology Unit - University of Pisa, Pisa, Italy, 5Dermatology Unit - University of Pisa, Pisa, Italy

    Background/Purpose: To assess skin involvement in a cohort of patients with systemic sclerosis (SSc) comparing results obtained from modified Rodnan skin score (mRSS), durometry and…
  • Abstract Number: 0046 • ACR Convergence 2021

    Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts

    Hanna Johnsson1, John Cole1, Stefan Siebert1, Iain McInnes2 and Gerard Graham1, 1University of Glasgow, Glasgow, United Kingdom, 2University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: Up to 30% of patients with psoriasis develop psoriatic arthritis (PsA). The traditional assumption is that the skin disease is the same in both…
  • Abstract Number: 0061 • ACR Convergence 2021

    Harnessing Spatially-Resolved Gene Expression to Characterize the Transcriptional Landscape of Psoriatic Skin

    Rochelle Castillo1, Ikjot Sidhu1, Di Yan1, Piotr Konieczny1, Rebecca Haberman1, Brandon Hsieh1, Andrea Neimann1, Shruti Naik1 and Jose Scher2, 1NYU Langone Health, New York, NY, 2New York University School of Medicine, New York, NY

    Background/Purpose: The skin is recognized as a window into the immunopathogenic mechanisms in the psoriatic arthritis (PsA) joint. This is evidenced by the fact that…
  • Abstract Number: 0356 • ACR Convergence 2021

    The Role of Neutrophils in the Clinical Severity of Lupus Nephritis Patients with Concurrent Skin Disease

    Lais Osmani, Sicong Shan, Zoe Chafouleas, Jason Pettus and Sladjana Skopelja-Gardner, Dartmouth Hitchcock Medical Center, Lebanon, NH

    Background/Purpose: Skin disease affects >80% of lupus patients and has been linked to lupus nephritis (LN) flares. We recently found that skin inflammation caused by…
  • Abstract Number: 0513 • ACR Convergence 2021

    Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood

    DeAnna Diaz1, Thomas Vazquez2, Christina Bax3, Jay Patel4, Madison Grinnell5, Emily Keyes6, Yubin Li5 and Victoria Werth7, 1Philadelphia College of Medicine, Philadelphia, PA, 2FIU Wertheim College of Medicine, Virginia Beach, VA, 3Corporal Michael J. Crescenz VAMC/ Department of Dermatology, U Penn, Philadelphia, PA, 4Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, 5Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, 6Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Our group has previously shown that Spirulina, a popular herbal supplement with purported immune boosting effects, is temporally associated with dermatomyositis (DM) onset and…
  • Abstract Number: 0545 • ACR Convergence 2021

    SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells

    Ellen Model, Morgan Omara, Pamela Palisoc, Dinesh Khanna and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI

    Background/Purpose: Vascular abnormalities in systemic sclerosis (SSc) are characterized by injury to vascular wall and extensive damage of the microvessels. It has been shown that…
  • Abstract Number: 0546 • ACR Convergence 2021

    Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis

    Kristina Clark1, Eszter Csomor2, Corrado Campochiaro3, Adam Taylor4, Yee Voan Teo2, Katherine Nevin2, Mary Morse2, Voon Ong5, Emma Derrett-Smith6, Nicolas Wisniacki2, Shaun Flint2 and Christopher Denton7, 1University College London, London, United Kingdom, 2GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 3Royal Free Hospital London, London, United Kingdom, 4GlaxoSmithKline, London, United Kingdom, 5University College London Medical School Royal Free Campus, London, United Kingdom, 6University College London Division of Medicine, London, United Kingdom, 7University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
  • Abstract Number: 0555 • ACR Convergence 2021

    Pathway-Driven Drug Repositioning in Systemic Sclerosis from Omics Data

    Dillon Popovich1, Tamar Abel1, Noelle Kosarek2, Monica Espinoza3, Rezvan Parvizi4, Jonathan Garlick5 and Michael Whitfield4, 1Geisel School of Medicine, West Lebanon, NH, 2Dartmouth Geisel School of Medicine, Hartford, VT, 3Geisel School of Medicine, Hanover, NH, 4Geisel School of Medicine, Lebanon, NH, 5Tufts University School of Dental Medicine, Boston, MA

    Background/Purpose: Omic analyses of systemic sclerosis (SSc) skin biopsy datasets identified distinct sets of patients that respond differently to treatment. The goal of this study…
  • Abstract Number: 0557 • ACR Convergence 2021

    The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway

    Christopher Wasson1, Eva Clavane2, Rebecca Ross1, Paul Meakin2 and Francesco Del Galdo3, 1LIRMM University of Leeds, Leeds, United Kingdom, 2LICAMM University of Leeds, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…
  • Abstract Number: L09 • ACR Convergence 2020

    A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)

    Dinesh Khanna1, Christopher Denton2, Daniel Furst3, Maureen Mayes4, Marco Matucci-Cerinic5, Vanessa Smith6, Dick de Vries7, Liesbeth Deberdt8, Pieter‑Jan Stiers8, Niyati Prasad8 and Sohail Ahmed9, 1University of Michigan, Ann Arbor, MI, 2Royal Free Hospital, University College London, London, United Kingdom, 3David Geffen School of Medicine at UCLA, Los Angeles, CA, 4University of Texas Health Science Center at Houston, Houston, TX, 5Università degli Studi di Firenze, Firenze, Italy, 6Ghent University Hospital, Ghent, Belgium, 7Galapagos BV, Leiden, Netherlands, 8Galapagos NV, Mechelen, Belgium, 9Ahmed Science Medicine, Basel, Switzerland

    Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…
  • Abstract Number: L10 • ACR Convergence 2020

    Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734

    Victoria Werth1, Jodi Karnell2, William Rees2, Nanette Mittereder3, Li Yan2, Yanping Wu3, Jorn Drappa2, Gabor Illei2 and John Ratchford2, 1University of Pennsylvania, Philadelphia, PA, 2Viela Bio, Gaithersburg, MD, 3Viela Bio, Gaithersburg

    Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…
  • Abstract Number: 1397 • ACR Convergence 2020

    Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort

    Smriti Prasad1, Samantha Black2, Shivani Sharma3 and Heidi Jacobe1, 1University of Texas Southwestern Medical Center, Dallas, TX, 2The University of Texas Southwestern Medical Center, Dallas, TX, 3University of Texas Southwestern, Dallas, TX

    Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
  • Abstract Number: 1610 • ACR Convergence 2020

    Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India

    Sandeep Surendran1, Mithun CB1, Arun Tiwari2, Vishal Marwaha1 and Sekhar Easwar1, 1Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, Kerala, India, 2Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, India

    Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology